Supplementary Table 1 from The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy

https://doi.org/10.1158/1541-7786.22526486

dataset

posted on 2023-04-03, 19:45 authored by Jie Du, Fuqiang Chen, Jiahua Yu, Lijun Jiang, Meijuan Zhou

<p>Table S1. List of 28 hits from primary screen. The CAS No. and tradenames of each drug are also listed.</p>

Funding

National Natural Science Foundation of China

China Postdoctoral Science Foundation

History

Related Materials

1.
DOI - Is supplement to The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy

ARTICLE ABSTRACT

In summary, our findings suggested the possibility for repurposing these candidates as radio- or chemosensitizers, which might extend their clinical application in cancer therapy.

Usage metrics

Keywords

Chemotherapy Combination chemotherapy Dna Damage And Repair DNA repair Drug Discovery Technologies Screening strategies (assays and chemical libraries)Radiation Oncology Radioprotectors and radiosensitizers Radiobiology Radiation-induced DNA damage

Licence

CC BY